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 Abstract 
Diabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with 
hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from 
hyperglycemia that can activate cellular signaling pathways transcription of factor NF-κB which stimulates the 
production of several inflammatory mediators andl lead to chronic inflammation. Chronic inflammation is implicated in 
β-cell damage and function and promotes apoptosis. EMSA Eritin is a polyherbal consisting of soy bean extracts, 
coconut water extract and red rice extract that assumed to be antidiabetic and anti-inflammatory. This study will assess 
the effectiveness of EMSA Eritin against inflammation in diabetes mellitus by measuring levels of NF-κB produced by 
immunocompetent cells in DM mice model. Streptozotocin 100 mg.kg
-1
 BW is used to induce diabetes mellitus in mice. 
Oral administration of EMSA Eritin was given for 14 days with dose of 0.3125 mg.g
-1
 BW, 3.125 mg.g
-1 
BW and 31.25 
mg.g
-1
 BW. Data were analyzed using One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The 
results showed that EMSA Eritin can be used as an alternative therapy for the treatment of DM. The level of NF-κB in 
diabetic mice significantly decreased when the mice received EMSA Eritin.  
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INTRODUCTION 
Diabetes mellitus is one of the most common 
metabolic disorders with increasing prevalence 
during recent years. Changes in lifestyle, diet and 
environment becomes the causes of the 
increasing prevalence of this disease. Prevalence 
occurred in Asia and Africa, as a result of 
urbanization trend and lifestyle changes [1]. 
Statistical data confirmed that diabetes has 
reached epidemic proportions. More than 346 
million people world wide have diabetes and it is 
predicted to be the seventh leading cause of 
death in the world by 2030 [2]. Meanwhile, the 
number of patients with DM in Indonesia 
reached 8.6 million in 2000 and will increase to 
21.3 million by 2030. Due to the high number of 
deaths, Indonesia was ranked 4th in the world 
after United States, India and China [3]. 
Diabetes mellitus characterized by hyper-
glycemia that occurs because the body is unable 
to secrete insulin in sufficient amounts or is 
unable to use insulin effectively or both [4,5,6]. 
DM can be a consequence of the reduction in the 
number of insulin receptors or failure in the 
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insulin-receptor binding, and failure in the 
transport of glucose into cells by the protein 
glucose transporter (GLUT) [7]. Previous research 
suggested that oxidative stress and inflammation 
play an important role in the development of DM 
[8]. 
Among various factors that are being involved 
in the progression of DM, oxidative stress could 
be typically induced by excessive nutritional 
factors like glucose and free fatty acids (FFA) 
which increasing formation of free radicals, auto 
oxidation of glucose and lipid peroxidation. In the 
process of oxidative stress, excessive reactive 
oxygen species (ROS) such as superoxide anion, 
hydroxyl radicals and hydrogen peroxide were 
produced by mitochondria and plasma mem-
brane [9]. ROS can activate cellular signaling 
pathways such as nuclear factor-κB (NF-κB), 
which stimulates the production of several 
inflammatory mediators. Recent finding suggest 
that proinflammatory cytokines such as 
interleukin-1 (IL-1), interleukin-6 (IL-6) and TNF-
α, play important roles in the pathophysiology of 
DM [7,9]. NF-κB first became a main suspect in 
the development of insulin resistance and 
diabetes after the milestone discovery that the 
anti-inflammatory agent, aspirin inhibits NF-κB 
and prevents degradation of the NF-κB inhibitor, 
IκB [10]. NF-κB which is involved in proinfla-
mmatory cytokines production and in the 
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induction of ROS-mediated NF-κB activation, may 
be important in etiology of DM and related 
complications [11]. 
Appropriately prescribed drugs such as 
sulfonylureas or thiazolidinediones as monothe-
rapy or add-on treatment are essential to cure 
the disease. However, many patients still cannot 
achieve satisfactory glycemic goals and even 
experienced serious side effects. Therefore, 
searching for alternative protective strategies 
becomes great interest. Recently, interests have 
been growing in the application of natural com-
ponents as antidiabetic agents whicth have fewer 
side effects, cheap and easy to obtain [12,13]. 
EMSA Eritin is a dietary supplement that consist-
ing of soy bean, coconut water and brown rice 
extract. Polyphenol compounds such as isofla-
vones and flavonoids, found in soy and red rice 
and mneral from coconut water known have 
antioxidant activity, anti-inflammatory, and anti-
diabetic to prevent β-cell apoptosis, increasing β-
cell proliferation, secretion and activity of insulin 
[13,14,15]. Based on these references, poly 
herbal EMSA Eritin is believed to be useful in the 
process of DM treatments. Therefore, this study 
will assess the effectiveness of EMSA Eritin 
towards inflammation in DM by measuring levels 
of the transcrip-tion factor of inflammatory, NF-
κB produced by immunocompetent cells in 
diabetes mellitus mice model with streptozotocin 
induced. 
 
MATERIALS AND METHODS 
Animal and research protocol approval 
Healthy Balb/c mice (25-35 g) were purchased 
from the Central Animal Room, Cellular and 
Molecular Biology Laboratory, University of 
Brawijaya. The mice were maintained in a 
temperature and humidity-regulated room with 
controlled lighting (12-h light/dark cycle). The 
animals were given standard pellets and tap 
water was provided ad libitum. 
 
Experimental design 
Total of 25 Balb/c female mice, between the 
ages of 4-6 weeks were used and divided into 5 
groups of treatment include negative control 
(healthy mice and without EMSA Eritin 
administration) and positive control (diabetic 
mice with EMSA Eritin administration). EMSA 
Eritin was grouped into three doses: Low dose 
(0.3125 mg.g
-1
 BW), optimum dose (3.125 mg.g
-1 
BW) and high dose (31.25 mg.g-1 BW). Each 
treatment was repeated 5 times.  
 
Drugs solution 
Streptozotocin was dissolved in 0.1 M citrate 
buffer (pH 4.5). EMSA Eritin was dissolved in 
aquades. 
 
Induction of diabetes 
Streptozotocin (100 mg.kg-1, i.p.) was admi-
nistered to induce diabetes to 5-day-old female 
mice [4]. The mice were grown, fed and water by 
ad libitum. Mice were weaned at 4 weeks old and 
selected for screening by glucometer glucose 
tolerance test. Mice with glucose level ≥ 200 
mg.dl-1 were considered to be diabetic and 
included in the research. 
 
Oral administration of EMSA Eritin  
Positive diabetic mice were given EMSA Eritin 
orally at a dose of 0 mg.g-1 BW (N); 0.3125 mg.g-1 
BW (D1); 3.125 mg.g-1 BW (D2); and 31,25 mg.g-1 
BW (D3). The dose is obtained from the 
conversion of the human dose that is 250 mg.kg-1 
BW. EMSA Eritin of all doses was freshly 
prepared twice a day before administration and 
given orally by syringe at 9:00 a.m. and 03.00 
p.m. Administration was conducted for 14 days. 
Blood glucose levels were measured every 3 days 
during the administration of EMSA Eritin to 
determine the change of blood glucose level. 
 
Lymphocyte isolation 
Mice were sectioned after 14 days treatment. 
Spleen were isolated and crushed in petri dish 
containing PBS. Lymphocyte homogenates were 
filtered using BD nylon cell strainerTM (100μm) 
and transferred into a new propylene tubes. 
Homogenates were centrifuged at 2500 rpm, 4°C 
for 5 min. Supernatant was removed and pellet 
resuspended in 1 mL PBS. 
 
Antibody staining and flowcytometry analysis 
Pellet stained with antibodies with extra-
cellular and intracellular staining. The following 
antibodies were used for extracellular staining 
are fluorescein isothiocyanate (FITC)-conjugated 
anti-mouse CD4, phycoerythrin (PE)-conjugated 
anti-mouse CD8, and fluorescein isothiocyanate 
(FITC)-conjugated anti-mouse CD68. Antibodies 
used for intracellular staining is PE-Cy5 conjuga-
ted anti-mouse NF-κB. 
For extracelluler staining, cells were stained 
with 1μL of extracellular antibody that had been 
diluted with 50 μL of PBS, and then incubated in 
ice box (4°C) for 20 minutes. For intracellular 
staining, cells were stained with extracellular 
antibody first and incubated in ice box (4°C) for 
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20 minutes. After that, cells were added with 50 
μL fixative solution (cytofix/cytosperm) and 
incubated again in ice box (4°C) for 20 minutes. 
Cells were added with 500 μL washperm to 
removes the fixative solution and centrifuged at 
2500 rpm, 4°C for 5 min. Pellet was stained with 
intracellular antibodies and then incubated in ice 
box (4°C) for 20 minutes. Suspension then was 
added with 300 μL PBS, transferred to flow 
cytometry cuvet and ready for analyzed with flow 
cytometry. 
 
Statistical analysis 
The data were evaluated by one-way ANOVA 
using the SPSS 16.0 program for Windows. The 
differences between the means assessed using 
Duncan's multiple range test. Statistical signifi-
cance was considered at p<0.05. 
 
RESULTS  
EMSA Eritin suppressed NF-κB in T lymphocyte 
Nuclear translocation of NF-κB in response to 
inflammatory insults is the primary regulatory 
step for its activation. NF-κB showed high 
expression in diabetic mice compared with 
normal mice (Fig. 1). STZ injection in the diabetic 
group (DM) can significantly increase the relative 
number of CD4+ T cells NF-κB+ 0.06 ± 0.01% 
compared to the healthy group (N) 0.04%. EMSA 
Eritin which administered in diabetic mice 
showed immunomodulatory activity as immune-
supresant of NF-κB which produced by CD4 
lymphocyte T cells. The relative number of 
CD4+NF-κB+ T cells in EMSA Eritin treatment 
group (D1-DM, D2-DM, and D3-DM) was 
significantly decrease (p<0.05) compared with 
control group (N). The low dose, normal dose and 
high dose of EMSA Eritin can suppress the level 
of CD4+NF-κB+ with the relative number 0.02%, 
0.04% and 0.01%, respectively. 
EMSA Eritin also showed suppression activity 
of NF-κB that produced by CD8 T cells (Fig. 2). 
The relative number of NF-κB in negative control 
(DM) is 0.04% and increased after STZ injection 
0.11%. Relative number of CD8+NF-κB+ T cells in 
all of dose of EMSA Eritin treatment group was 
lower than negative control group (DM), with the 
value of each are 0.05%, 0.05% and 0.08% 
(p>0.05). NF-κB that produced by CD4 and CD8 T 
cells was decreased in all doses of EMSA Eritin 
treatments. The relative number of NF-κB in 
treatment groups did not show a significant 
difference with healthy group. This result showed 
that the treatment group of diabetic mice had 
returned to normal condition or became 
healthier. 
 
     
(a)                                                                                  (b) 
Figure 1. EMSA Eritin decrease relative number of NF-κB on CD4+ T cells. 
Description: 
N: healthy mice group,  
DM: diabetic mice group were treated with EMSA Eritin 0 mg.g-1 BW;  
D1-DM = diabetic mice group were treated with Emsa Eritin low dose 0.3125 mg.g-1 BW;  
D2-DM = diabetic mice group were treated with Emsa Eritin normal dose 3.125 mg.g-1 BW;  
D3-DM = diabetic mice group were treated with Emsa Eritin high dose 31.25 mg.g-1 BW.  
(a) The percentage of CD4+ T cells expressing positive NF-κB using flow cytometry.  
(b) The bars are the number of CD4 T cells expressing positive NF-κB on the spleen cells of mice after EMSA Eritin treatment.  
The data are mean+SD in each group with p value < 0.05. 
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(a)                                                                              (b) 
Figure 2. EMSA Eritin decrease relative number of NF-κB on CD8+ T cells 
Description: 
N: healthy mice group  
DM: diabetic mice group were treated with EMSA Eritin 0 mg.g-1 BW;  
D1-DM = diabetic mice group were treated with Emsa Eritin low dose 0.3125 mg.g-1 BW;  
D2-DM = diabetic mice group were treated with Emsa Eritin normal dose 3.125 mg/gr BW;  
D3-DM = diabetic mice group were treated with Emsa Eritin high dose 31.25 mg.g-1 BW.  
(a) The percentage of CD8+ T cells expressing positive NF-κB using flow cytometry.  
(b) The bars are the number of CD8+ T cells expressing positive NF-κB on the spleen cells of mice after EMSA Eritin treatment. 
Data are mean±SD in each group with p value < 0.05. 
 
EMSA Eritin suppressed NF-κB in macrophage 
cells (CD68+) 
We also found that administered EMSA Eritin 
decreased the level of NF-κB that is produced by 
CD68 macrophage cells (Fig. 3). NF-κB was 
increased significantly (p<0.05) after mice got 
induction of STZ (0.26%) compared to healthy 
mice (0.11%) in Fig.3. The relative number of NF-
κB in all dose treatment showed significant 
difference compared to negative control group 
(DM) with the value of 0.17%, 0.20% and 0.14%, 
respectively. It showed that the treatment of 
EMSA Eritin improve the diabetic condition to be 
better. Increased levels of NF-κB would lead to 
proliferation of CD4 T cells, CD8 T cells and CD68 
macrophage cells to produce proinflammatory 
cytokines that essential in the development of 
diabetes mellitus. 
 
      
(a)                                                                              (b) 
Figure 3. EMSA Eritin decrease relative number of NF-κB on CD68+ macrophage cells 
Description: 
N: healthy mice group,  
DM: diabetic mice group were treated with EMSA Eritin 0 mg.g-1 BW;  
D1-DM = diabetic mice group were treated with Emsa Eritin low dose 0.3125 mg.g-1 BW;  
D2-DM = diabetic mice group were treated with Emsa Eritin normal dose 3.125 mg.g-1 BW;  
D3-DM = diabetic mice group were treated with Emsa Eritin high dose 31.25 mg.g-1 BW).  
(a) Bars are number of CD68+ macrophage cells expressing positive NF-κB on spleen cells of mice after EMSA Eritin treatment.  
(b) The percentage of CD68+ macrophage cells expressing positive NF-κB using flow cytometry.  
The data are mean±SD in each group with p value < 0.05. 
 J.Exp. Life Sci. Vol. 5 No. 1, 2015  ISSN. 2087-2852 
  E-ISSN. 2338-1655 
28 EMSA Eritin Blocks Nuclear Factor-Kappa B in Diabetic Mice 
(Sihombing et al.) 
DISCUSSIONS 
Diabetes mellitus has been shown to be a 
state of free radicals over production resulting 
from hyperglycemia and FFA. Factors that 
attributed to the formation of free radicals may 
include not only elevated non-enzymatic and 
autooxidative glycosylation, but also metabolic 
stress as a result of alterations in energy 
metabolism, inflammatory mediators levels and 
the status of antioxidant defense [16]. In the 
process of oxidative stress, ROS primarily 
produced by mitochondria excessively. ROS 
activates cellular signaling pathways nuclear 
factor-κB (NF-κB) which stimulates the 
production of several mediators of proinflamma-
tory cytokines such as IL-1, IL-6 and TNF-α *9]. 
The novel finding of the current study is that 
NF-κB is involved in the development of 
inflammation-associated metabolic diseases such 
as diabetes mellitus. NF-κB, or nuclear factor κB, 
is a nuclear transcription factor found in all cell 
types. It is involved in cellular responses to 
stimuli such as stress, cytokines, free radicals, 
ultraviolet irradiation, bacterial or viral antigens 
and activation of the adaptive immune receptors 
like TLR4 in response to FFA [10,17]. NF-κB 
promotes immunity by controlling the expression 
of genes involved in inflammation. NF-κB drives 
expression of target genes that mediate cell 
proliferation and release of cytokines to activate 
the immune response [17]. 
NF-κB is a transcription factor composed of 
p50 and p65 subunits (heterodimer) and 
expressed in the cytoplasm of virtually all cell 
types. Its activity is controlled by a family of 
regulatory proteins, called inhibitors of NF-κB 
(IκB). In the non-active condition, NF-κB in the 
cytoplasm constitute as heterodimer that binds 
to Iκβ which responsible for the activation of NF-
κB. NF-kB activity is under the control of signaling 
from extracellular stimuli. Cytokine or PAMP 
ligation of cell surface receptors initiates 
signaling cascades that converge on the 
activation of the inhibitor of kB kinase (IKK) 
complex. The IKK complex consists of three 
subunits: the catalytic subunits IKKα and IKKβ, 
and the regulatory subunit IKKγ. IKK 
phosphorylation of IkB molecules promotes their 
degradation and releases heterodimers p65 and 
p50 NF-kB dissociation from IKKα [17]. NF-κB 
binds to NF-κB binding domain on gene promoter 
and regulate the transcription of genes involved 
in innate immunity and inflammation. [18]. NF-κB 
signaling pathway can be activated by many 
proinflammatory stimuli such as TNF-α which is 
not only being the activator of NF-kB but also a 
regulation product of NF-κB [7]. 
EMSA Eritin showed anti-inflammatory active-
ty when administered to the lymphocytes in mice 
model diabetes mellitus. EMSA Eritin reduced the 
level of NF-κB that produced by CD4 T cells, CD8 
T cells and CD68 macrophage cells. EMSA Eritin is 
a polyherbal that consists of soy bean extract, 
coconut water extract and red rice extract. This 
composition seem to be effective to suppress the 
transcription factor of inflammation, NF-κB. Soy 
isoflavone genistein is one of the active 
compound on EMSA Eritin and has been reported 
to be protective agent for diabetes by regulation 
of oxidative stress and inflammation as it 
decreases lipid peroxidation, inhibits cyclooxy-
genase expression and myeloperoxidase activity 
as well as reacts with free radicals and 
neutralizes their effects [16]. Anthocyanin, 
especially C3G (cyanide-3-O-β-glucoside) is red 
rice pigment had antioxidative and anti-
inflammatory activity [19]. Meanwhile, coconut 
water extract contains L-arginine, ascorbic acid, 
minerals such as calcium, magnesium and 
potassium which have hypolipidemic and 
antidiabetic activity [15]. 
Previous researches reported that genistein 
and anthocyanin can interfere NF-κB signaling by 
blocking translocation NF-κB p65 to nucleus, 
reduce JNK activation and reduce IκBα 
phosphorylation, thus interfere transcription 
genes that role in the inflammation [20,21]. 
Biological activity of genistein and anthocyanins 
directly inhibit p50-p65 NF-κB binding to the 
target of gene promoter NF-κB, stabilization of 
IκBα by inhibit the phosphorylation of IκBα by 
IKK-β. Thus the translocation of NF-κB into the 
nucleus can be blocked and transcription process 
will not occur [18]. In addition, L-arginine can 
inhibit the reaction of non-enzymatic glycosy-
lation of proteins and the formation of AGEs by 
inhibiting the covalent modification proteins or 
AGEs formation [22]. AGE will increases ROS and 
triggers the MAPK and NF-κB signaling pathway. 
MAPK activation will trigger macrophage activity 
to synthesizes cytokine pro inflammation [23]. 
Inhibition of AGEs by L-arginine will reduce NF-κB 
activation.  
 
CONCLUSION 
The major findings of our study are: (i) NF-κB 
expressions that produce by CD4 T cells, CD8 T 
cells and CD68 macrophage cells are increased in 
diabetic mice and (ii) treatment with EMSA Eritin 
could decrease the NF-κB level. This findings 
 J.Exp. Life Sci. Vol. 5 No. 1, 2015  ISSN. 2087-2852 
  E-ISSN. 2338-1655 
29 EMSA Eritin Blocks Nuclear Factor-Kappa B in Diabetic Mice 
(Sihombing et al.) 
suggest that NF-κB might be an important 
molecule contributing to diabetes mellitus and its 
complication. 
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